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Abstract 40 
Synovial sarcoma tumours contain a characteristic fusion protein, SS18-SSX, which 41 
drives disease development. Targeting oncogenic fusion proteins presents an 42 
attractive therapeutic opportunity. However, SS18-SSX has proven intractable for 43 
therapeutic intervention. Using a domain-focused CRISPR screen we identified the 44 
bromodomain of BRD9 as a critical functional dependency in synovial sarcoma. 45 
BRD9 is a component of SS18-SSX containing BAF complexes in synovial sarcoma 46 
cells; and integration of BRD9 into these complexes is critical for cell growth. 47 
Moreover BRD9 and SS18-SSX co-localize extensively on the synovial sarcoma 48 
genome. Remarkably, synovial sarcoma cells are highly sensitive to a novel small 49 
molecule degrader of BRD9, while other sarcoma subtypes are unaffected. 50 
Degradation of BRD9 induces downregulation of oncogenic transcriptional programs 51 
and inhibits tumour progression in vivo. We demonstrate that BRD9 supports 52 
oncogenic mechanisms underlying the SS18-SSX fusion in synovial sarcoma and 53 
highlight targeted degradation of BRD9 as a potential therapeutic opportunity in this 54 
disease. 55 
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Introduction 75 
Sarcomas although rare in adult patients account for up to 20% of all paediatric 76 
malignancies (1). These are often aggressive diseases which do not respond well to 77 
conventional therapeutic interventions (2). As such the cure rates for many of these 78 
diseases are unsatisfactory and patient prognoses remain poor. The molecular 79 
pathology of many of these cancers is associated with recurrent chromosomal 80 
rearrangements; leading to the generation of chimeric fusion proteins. Significantly, 81 
many fusion protein generating aberrations occur in a genomic background with few 82 
co-occurring genetic alterations (3–8). This has led to the prevailing notion that these 83 
gene fusions are often the primary driver of disease development. These 84 
chromosomal rearrangements often effect genes involved in 85 
transcriptional/chromatin regulatory mechanisms; with the resulting fusion proteins 86 
thought to drive disease development by altering the dynamics of transcriptional 87 
control. Excitingly, recent work has highlighted the therapeutic potential of targeting 88 
mechanisms of transcriptional control in cancer cells (9). However, effective means 89 
of blocking oncogenic transcriptional mechanisms in fusion gene driven sarcomas 90 
are currently lacking.  91 
 92 
Synovial sarcoma is a fusion gene driven malignancy, which accounts for ~10% of 93 
soft-tissue sarcomas. Synovial sarcoma is a poorly differentiated malignancy with an 94 
often aggressive clinical progression. It occurs in patients of all ages, but is 95 
particularly common in children and young adults with a peak incidence between 20-96 
30 years of age. The hallmark genetic abnormality in synovial sarcoma is a recurrent 97 
t(X;18) chromosomal rearrangement. This fuses the SS18 gene (also known as 98 
SYT) on chromosome 18 to one of three related genes SSX1, SSX2 and SSX4 on 99 
the X chromosome(10–12). This fusion is considered pathognomonic for the 100 
disease, with diagnoses confirmed by RT-PCR and karyotyping analyses to identify 101 
the fusion event. As such, essentially 100% of synovial sarcoma tumours contain an 102 
SS18-SSX fusion. The SS18-SSX rearrangement is often the only genetic 103 
abnormality in synovial sarcoma tumours (13, 14); suggesting that it is the primary 104 
driver of disease. Indeed, conditional expression of SS18-SSX in muscle progenitor 105 
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cells leads to development of a fully penetrant synovial sarcoma like disease in mice 106 
(15).     107 
 108 
The SS18-SSX fusion protein is believed to function as an aberrant transcriptional 109 
regulator. The SS18 protein is a dedicated component of the chromatin remodelling 110 
BAF (also known as SWI/SNF) complex which functions primarily in transcriptional 111 
activation (16, 17). Whereas the SSX proteins are thought to function in gene 112 
silencing; potentially through interactions with the Polycomb Repressive Complex 113 
(PRC)1 (18, 19). SS18-SSX dominantly assembles into BAF complexes in synovial 114 
sarcoma cells, leading to eviction of the wildtype SS18 and SNF5 proteins from the 115 
complex. This altered complex assembly is redistributed on chromatin and drives an 116 
expression signature required to maintain the proliferative/undifferentiated state of 117 
synovial sarcoma cells (20, 21). SS18-SSX chromatin binding is directed in part 118 
through interactions with the PRC1.1 complex; mediated by the SSX portion of the 119 
fusion (21). The recruitment of SS18-SSX to chromatin via interactions with PRC1.1 120 
is essential for the oncogenic function of the fusion. Moreover, association of SS18-121 
SSX with DNA-binding transcription factors has also been suggested to be important 122 
for chromatin binding and oncogenic activities (22). Recruitment of BAF complex 123 
activity to SS18-SSX bound regions is essential for transcriptional activation of fusion 124 
target genes (20, 21, 23). Depletion of SS18-SSX protein levels leads to reduced 125 
BAF complex binding at target sites and repression of fusion target genes. These 126 
findings highlight that SS18-SSX driven alterations in chromatin regulatory pathways 127 
are a key aspect of synovial sarcoma oncogenesis. Moreover, they highlight that 128 
targeting mechanisms related to fusion protein recruitment and BAF complex 129 
function may provide a therapeutic opportunity in this disease. However, to date 130 
robust approaches for targeting these mechanisms have not been described. 131 
 132 
Here using a custom CRISPR/Cas9 based functional genomics approach focused on 133 
chromatin regulatory genes we identify the bromodomain of BRD9 as a vulnerability 134 
in synovial sarcoma cells. We show that BRD9 is part of SS18-SSX containing BAF 135 
complexes in synovial sarcoma cells; and that the association of BRD9 with the BAF 136 
complex is functionally essential. Targeting BRD9 with a novel chemical degrader 137 
specifically impedes synovial sarcoma cell viability; eliciting more robust therapeutic 138 
effects than BRD9 inhibition using bromodomain targeting chemical probes. 139 
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Importantly, BRD9 is required to maintain appropriate expression of an oncogenic 140 
gene expression signature driven by SS18-SSX. Taken together, our findings 141 
highlight BRD9 as a novel therapeutic target in synovial sarcoma.   142 
 143 
 144 
Results 145 
The BRD9 bromodomain is a functional dependency in synovial sarcoma 146 
To identify functional chromatin based dependencies that may be amenable to 147 
therapeutic targeting in synovial sarcoma cells we used a CRISPR/Cas9 based 148 
domain focused pooled screening approach (24). To this end we generated a 149 
custom lentiviral sgRNA library targeting known functional regions in 193 chromatin 150 
regulatory proteins. Viral supernatants generated with this library were used to infect 151 
Cas9 expressing synovial and Ewing sarcoma cell lines. The relative abundance of 152 
individual sgRNAs within each population was compared between early and late time 153 
points by high-throughput sequencing (Figure 1A). These analyses demonstrated 154 
that 3 independent sgRNAs targeting the bromodomain of BRD9 were depleted from 155 
synovial, but not Ewing sarcoma cell cultures (Figure 1B-C, and Figure 1-source 156 
data 1 and 2). Remarkably, of the 52 bromodomains contained within 38 proteins 157 
targeted in this library, only the BRD9 bromodomain had all sgRNAs specifically 158 
depleted in synovial sarcoma cells (Figure 1-figure supplement 1A). This is in striking 159 
contrast to the bromodomains of BRD4 which are a dependency in both synovial and 160 
Ewing sarcoma cells, as well as several other malignancies (25, 26). To further 161 
examine the specificity of this dependency we performed individual sgRNA depletion 162 
assays in 2 independent synovial, Ewing and rhabdomyosarcoma cell lines, 163 
respectively. These experiments demonstrated that BRD9 bromodomain targeting 164 
sgRNAs were only depleted in synovial sarcoma cells (Figure 1D and Figure 1-165 
source data 3). Importantly, the sgRNAs used here have comparable or higher 166 
genome editing efficiencies in Ewing and rhabdomyosarcoma cell lines, compared to 167 
synovial sarcoma cells (Figure 1-figure supplement 1B and data not shown). This 168 
indicates that differences in sgRNA depletion cannot be attributed to discrepancies in 169 
sgRNA editing. Moreover, BRD9 expression levels are consistent across all cell lines 170 
tested, indicating that differences in BRD9 levels do not reflect altered sensitivity to 171 
BRD9 targeting (Figure 1-figure supplement 1C). Using an independent shRNA-172 
based approach we observed similar synovial sarcoma specific effects following 173 
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knockdown of BRD9 protein levels (Figure 1-figure supplement 1D-G). Consistent 174 
with this, within the recently published Project DRIVE (27) database we observe, that 175 
among the almost 400 cancer cell lines assayed, synovial sarcoma cell lines are the 176 
most sensitive to BRD9 targeting (Figure 1E). To confirm the importance of the 177 
BRD9 bromodomain we performed functional rescue experiments. We generated a 178 
full-length human BRD9 cDNA containing silent point mutations within the sgRNA 179 
recognition sequence, conferring resistance to Cas9 targeting (Figure 1-figure 180 
supplement 1H). Next, we expressed a full-length (FL), bromodomain deleted 181 
(bromo) or bromodomain inactivated (N216A) version of this cDNA in synovial 182 
sarcoma cells. This demonstrated that only wildtype full-length BRD9 can rescue the 183 
depletion of sgRNAs targeting the bromodomain (Figure 1F, Figure 1-source data 4, 184 
Figure 1-figure supplement 1I). This indicates that BRD9, and the BRD9 185 
bromodomain, are selective functional dependencies in synovial sarcoma; 186 
highlighting a novel therapeutic target in this disease. 187 
 188 
BRD9 is a component of SS18-SSX containing BAF complexes 189 
BRD9 has previously been shown to be a component of the BAF complex in several 190 
normal tissues (28). Moreover, biochemical studies in HEK293T cells have indicated 191 
that BRD9 can also associate with SS18-SSX containing complexes in this setting 192 
(16). However, it is unknown whether BRD9 is part of the oncogenic SS18-SSX 193 
containing BAF complex in synovial sarcoma cells. Consistent with previous results 194 
we found that BRD9 associates with exogenously expressed SS18-SSX1/2 in 195 
HEK293T cells (Figure 2-figure supplement 1A-C, Figure 2-figure supplement-source 196 
data 1-3). Next, to test whether SS18-SSX fusions also interact with BRD9 in 197 
synovial sarcoma cells, we immunoprecipitated the endogenous fusion protein in 2 198 
independent synovial sarcoma cell lines (Figure 2A). Significantly, these experiments 199 
demonstrated that BRD9 co-purifies with endogenous SS18-SSX containing BAF 200 
complexes in synovial sarcoma cells (Figure 2B, Figure 2-source data 1 and 2, 201 
Figure 2-figure supplement 1D and Figure 2-figure supplement 1-source data 4). 202 
Moreover, SS18-SSX fusion proteins co-purify with BRD9 in reciprocal endogenous 203 
IP experiments (Figure 2C and D). A recent report indicates that BRD9 is a member 204 
of a novel subclass of BAF complex(es), termed GBAF (for GLTSCR1/1L-BAF) (29). 205 
These complexes lack SNF5 and an ARID component and contain BRD9, GLTSCR1 206 
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or GLTSCR1L as defining complex members. Our proteomic analysis of endogenous 207 
SS18-SSX containing complexes identified peptides mapping to GLTSCR1, lending 208 
support to the notion that the fusion incorporates into GBAF assemblies containing 209 
BRD9 (Figure 2-figure supplement 1C and D). As such by combining genomic and 210 
proteomic approaches we have identified BRD9 as a functional dependency within 211 
SS18-SSX fusion protein containing BAF complexes in synovial sarcoma cells.  212 
 213 
To ascertain the relative proportion of individual BAF complex members in SS18-214 
SSX purifications we used the intensity-based absolute quantification (iBAQ) 215 
algorithim (30). This showed that core complex members such as SMARCC1, 216 
SMARCC2 and SMARCA4 have relative abundances approximately equal to, or 217 
greater than, SS18-SSX (Figure 2E); suggesting that these proteins co-exist with the 218 
fusion protein in most (if not all) complexes. However, the relative abundance of 219 
BRD9 (and GLTSCR1) is 10-20% that of SS18-SSX; indicating that these 220 
components are sub-stoichiometric members of SS18-SSX containing complexes. 221 
Interestingly, several of the BAF complex members (PBRM, SMARCA2 and 222 
SMARCA4) identified in these proteomics studies were included in our functional 223 
genomics screen (Figure 1A). However, no robust dependencies were evident 224 
among the bromodomains of these proteins which were targeted within our library 225 
(Figure 2-figure supplement 1E). Intriguingly, this suggests that the minor subset of 226 
BRD9 containing complexes are particularly important, and perhaps functionally 227 
specialised in synovial sarcoma cells.  228 
 229 
BRD9 functions within SS18-SSX containing complexes 230 
Next, we wanted to understand whether BRD9 executes any bromodomain 231 
independent functions in synovial sarcoma cells. To do this we used a high-density 232 
CRISPR mutagenesis approach, introducing 92 individual sgRNAs targeting across 233 
the BRD9 locus into Cas9 expressing synovial sarcoma cell lines. We monitored for 234 
changes in sgRNA expressing (GFP-positive) cells over time, and consistent with our 235 
pooled screen most sgRNAs targeting the BRD9 bromodomain were robustly out 236 
competed in these GFP depletion assays (Figure 2F and Figure 2-source data 3). 237 
However, we identified an additional hotspot of sgRNA depletion within a previously 238 
uncharacterised central region of BRD9 (amino acids 311-345). We confirmed the 239 
importance of this region with functional rescue experiments showing that a 311-240 
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345 BRD9 cDNA was incapable of rescuing the depletion of sgRNAs targeting this 241 
region (Figure 2G and Figure 2-source data 4). Strikingly, co-IP experiments found 242 
that while the BRD9 bromodomain is dispensable for BAF complex interaction, this 243 
novel functional region is essential for association with the complex (Figure 2H). 244 
These results identify a novel BAF complex interaction domain within BRD9 and 245 
demonstrate that association of BRD9 with the BAF complex is functionally essential 246 
in synovial sarcoma cells. 247 
 248 
BRD9 co-binds the synovial sarcoma genome with SS18-SSX 249 
To understand the extent to which BRD9 and SS18-SSX containing complexes 250 
overlap on chromatin we performed chromatin immunoprecipitation with next-251 
generation sequencing (ChIP-seq). Owing to a lack of high-quality ChIP-grade 252 
antibodies for BRD9 and SS18-SSX, we adapted a previously reported 253 
CRISPR/Cas9 based approach to knock-in a 3xHA epitope tag at the C-termini of 254 
the endogenous BRD9 and SS18-SSX1 loci in HSSYII cells (31) (Figure 3-figure 255 
supplement 1A). ChIP-seq analyses demonstrated that BRD9 and SS18-SSX1 bind 256 
broadly throughout the genome (Figure 3A); with ~35% of binding sites occurring at 257 
gene promoters and the remaining ~65% at distal inter- and intragenic regions 258 
(Figure 3B). Comparing the binding profiles of BRD9 and SS18-SSX1 demonstrated 259 
that these proteins co-localize extensively on the synovial sarcoma genome. Indeed, 260 
a clear majority of all identified BRD9 and SS18-SSX1 binding sites overlap (Figure 261 
3C), and there is a tight correlation in BRD9 and SS18-SSX1 occupancy genome-262 
wide (Figure 3-figure supplement 1B). Additional ChIP-seq analyses of RNA 263 
polymerase II (RNAPII) and the histone modification H3K27Ac further demonstrates 264 
that BRD9 and SS18-SSX1 bind virtually all active gene promoters and enhancer 265 
elements (Figure 3D and E). With little evidence of significant binding at inactive 266 
genomic loci. Two recent studies characterised gene expression signatures defining 267 
synovial sarcoma tumours, demonstrating that the SS18-SSX fusion directly binds 268 
many of these genes (20, 21). Importantly, we found a significant overlap between 269 
these previous SS18-SSX1 ChIP studies and our own epitope tag knock-in mediated 270 
SS18-SSX1 and BRD9 ChIP-seq experiments (Figure 3F and Figure 3-figure 271 
supplement 1C). Considering that BRD9 may be present in only ~15% of SS18-SSX 272 
containing complexes, such broad co-localisation is remarkable; and suggests BRD9 273 
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containing complexes play an important role in supporting SS18-SSX function 274 
genome-wide. 275 
 276 
BRD9 bromodomain inhibition 277 
Several recent studies have described the development of potent small-molecule 278 
inhibitors of the BRD9 bromodomain (32–34). To test the feasibility of small-molecule 279 
mediated targeting of the BRD9 bromodomain as a therapeutic approach in synovial 280 
sarcoma we performed dose response experiments using two independent BRD9 281 
inhibitors, BI7273 and I-BRD9. Consistent with our genetic data, synovial sarcoma 282 
cells were more sensitive to BRD9 bromodomain inhibition compared to other 283 
pediatric sarcomas (Figure 4A). However, these effects were modest with growth 284 
IC50 values in the M range. Interestingly, spike-in normalized BRD9 ChIP-seq 285 
(ChIP-Rx) performed in BI7273 treated cells demonstrated that while the chromatin 286 
occupancy of BRD9 is reduced in inhibitor treated cells some BRD9 remains 287 
associated with chromatin (Figure 4B). This indicates that BRD9 does not rely 288 
exclusively on bromodomain function to associate with chromatin. Consistent with 289 
this, mutational inactivation of the BRD9 bromodomain also leads to an incomplete 290 
loss of BRD9 binding across the genome (Figure 4-figure supplement 1A and B). 291 
Significantly, the ability of BRD9 to incorporate into the BAF complex is required for 292 
chromatin association, since deleting the BAF complex interaction domain (aa311-293 
345) leads to a similar reduction in chromatin binding as bromodomain deletion 294 
(Figure 4C and Figure 4-source data 1). Taken together, these data indicate that 295 
BRD9, as part of the BAF complex, can access chromatin in a bromodomain 296 
independent manner. Highlighting that bromodomain inhibition, while at least partially 297 
effective at blocking synovial sarcoma cell growth/survival, is unlikely to completely 298 
ablate the functional contributions of BRD9.   299 
 300 
Targeted degradation of the BRD9 protein 301 
To completely inactivate BRD9 function we leveraged our recent success developing 302 
a targeted chemical degrader of BRD9 (35). We created an optimized chemical 303 
analogue of our previous BRD9 degrader, dBRD9-A (Figure 4D). This molecule 304 
contains a more lipophilic alkyl linker and exhibits improved BRD9 degradation 305 
properties (data not shown). Importantly, dBRD9-A is a highly specific binder of the 306 
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BRD9 bromodomain (Figure 4E); and elicits near complete BRD9 degradation at low 307 
nanomolar concentrations (Figure 4F). These degradation effects are dependent on 308 
the E3 ubiquitin ligase component CRBN, as well as BRD9 bromodomain 309 
engagement (Figure 4-figure supplement 1B-C). ChIP-Rx experiments demonstrate 310 
a far more robust loss of BRD9 binding across the genome following dBRD9-A 311 
treatment; compared to BI7273 treatment (Figure 4G). Indeed, essentially no BRD9 312 
remains bound on chromatin following 24hrs of dBRD9-A treatment (Figure 4H). 313 
Significantly, BRD9 degradation leads to a greater therapeutic response than 314 
bromodomain inhibition (Figure 4I); consistent with the notion that BRD9 also 315 
functions independently of its bromodomain. Moreover, consistent with our genetic 316 
data other pediatric sarcoma subtypes are unaffected by BRD9 degradation (Figure 317 
4-figure supplement 1E-F). Interestingly, the observed increase in therapeutic 318 
response in dBRD9-A treated cells is not due to destabilisation of the SS18-SSX 319 
fusion itself (Figure 4-figure supplement 1G). However, quantitative interactions 320 
proteomics of SS18-SSX containing complexes in dBRD9-A treated cells 321 
demonstrate that the GBAF members (GLTSCR1/L), in addition to BRD9, are lost 322 
from fusion protein containing complexes following BRD9 degradation (Figure 4-323 
figure supplement 1H). This suggests that BRD9 is essential for the proper assembly 324 
of GBAF complexes; and that BRD9 degradation specifically disrupts this subclass of 325 
SS18-SSX containing complexes. Taken together, these data demonstrate that 326 
targeting BRD9 function with chemical degraders, rather than bromodomain 327 
inhibitors, is a more efficacious therapeutic approach in synovial sarcoma. 328 
 329 
BRD9 supports oncogenic transcription in synovial sarcoma 330 
Synovial sarcoma cells treated with dBRD9-A undergo a progressive cell cycle arrest 331 
(Figure 5A and Figure 5-source data 1), which is further associated with an increase 332 
in Annexin–V positivity (Figure 5B and Figure 5-source data 3). Consistent with the 333 
on-target activity of dBRD9-A, swapping the BRD9 bromodomain for the closely 334 
related BRD7 bromodomain (63%, sequence identity) renders BRD9 and synovial 335 
sarcoma cells insensitive to dBRD9-A treatment (Figure 5-figure supplement 1A-B 336 
and Figure 5-figure supplement 1-source data 1). Using an in vivo synovial sarcoma 337 
xenograft model, we found that treatment of mice with dBRD9-A over 24 days 338 
inhibited tumour progression (Figure 5C). We confirmed in vivo pharmacodynamic 339 
activity of dBRD9-A in this system by immunoblotting BRD9 in tumour tissue derived 340 
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from vehicle and dBRD9-A treated mice (Figure 5D). Mice treated with dBRD9-A did 341 
not suffer any overt side effects associated with treatment, retaining a normal body 342 
weight and blood counts (Figure 5-figure supplement 1C-D and and Figure 5-figure 343 
supplement 1-source data 2-3). Next we performed cell count normalized RNA-seq 344 
analysis to understand why synovial cells are effected by BRD9 degradation. We 345 
performed these experiments 6hrs after dBRD9-A treatment (the earliest time point 346 
where we observe complete BRD9 degradation) to allow characterisation of the 347 
primary molecular changes following BRD9 loss. Strikingly, degradation of BRD9 348 
primarily leads to down regulated gene expression (Figure 5E and Figure 5-source 349 
data 3). Using our H3K27Ac ChIP-seq data we identified the subset of genes 350 
associated with super enhancer (SE) elements; since studies have demonstrated 351 
that SE-associated genes are highly sensitive to transcriptional perturbation. 352 
Moreover, SEs drive expression of genes required for maintaining tumour cell 353 
identity (36, 37). Consistent with this, several genes associated with SEs in HSSYII 354 
cells including TWIST1 (38) and TLE1 (22) are known to play key functional roles in 355 
synovial sarcoma (Figure 5F). Moreover, expression of many of these genes has 356 
previously been linked to primary synovial sarcoma tumour phenotypes, defining 357 
both clinical and biological characteristics (20, 21, 39–43). SEs have higher BRD9 358 
and SS18-SSX1 occupancy levels compared to typical enhancers (Figure 5-figure 359 
supplement 1E); and BRD9 degradation leads to a preferential downregulation of SE 360 
associated gene expression (Figure 5G). Significantly, these genes depend on 361 
SS18-SSX1 to maintain their expression, since shRNA mediated knockdown of 362 
SS18-SSX1 leads to a collapse of SE associated gene expression (Figure 5H). 363 
dBRD9-A treatment and consequential downregulation of transcription is further 364 
associated with reductions in SS18-SSX1 binding at SEs (Figure 5I and Figure 5-365 
figure supplement 1F). Interestingly, since SS18-SSX1 and BRD9 directly bind the 366 
majority of active genes, these transcriptional perturbations amount to a relatively 367 
narrow impingement on the broader cohort of SS18-SSX downstream target genes 368 
(Figure 5-figure supplement 1G).   However, these data demonstrate that BRD9 is 369 
required to maintain the SE associated oncogenic transcriptional program driven by 370 
SS18-SSX and the phenotypic impact of BRD9 degradation underlines the functional 371 
importance of this gene cohort. Most importantly, these data show that targeting 372 
BRD9 using our novel degrader compound directly perturbs underlying oncogenic 373 
mechanisms in this disease.  374 
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 375 
Discussion 376 
We’ve shown that BRD9 is an essential SS18-SSX fusion protein co-factor in 377 
synovial sarcoma. Our data indicate that through assembly into SS18-SSX 378 
containing complexes BRD9 supports oncogenic gene expression programs 379 
necessary for synovial sarcoma oncogenesis. This is likely achieved, at least in part, 380 
via bromodomain mediated interactions with chromatin regions marked with acetyl-381 
lysine modifications. Indeed, we observe the greatest amount of BRD9 and SS18-382 
SSX binding at super enhancer elements associated with high levels of H3K27Ac. 383 
BRD9 may promote and/or stabilize binding of SS18-SSX containing complexes at 384 
acetylated chromatin regions; since loss of BRD9 can lead to reduced fusion protein 385 
occupancy at some super enhancers. This induces perturbations of oncogenic gene 386 
expression programs driven by the fusion protein and robust therapeutic effects. This 387 
work highlights the first actionable therapeutic vulnerability, directly linked to SS18-388 
SSX, in synovial sarcoma. These findings provide a rationale for future clinical 389 
investigations of BRD9 as a therapeutic target in synovial sarcoma patients.   390 
 391 
This work demonstrates that direct targeting of oncogenic, SS18-SSX containing 392 
BAF complexes is a viable therapeutic approach in synovial sarcoma. Recent work 393 
has indicated that BRD9 assembles into a previously unreported form of the BAF 394 
complex, termed GBAF (29). This complex is defined by the presence of either 395 
GLTSCR1 or GLTSCR1L and BRD9; and also lacks SNF5 and an ARID component. 396 
This altered complex assembly suggests potential functional specialization within 397 
BRD9 containing complexes. Therefore, it will be important to perform detailed 398 
structure/function studies to better understand the molecular contributions of these 399 
novel complexes. Interestingly, our finding that GLTSCR1 and GLTSCR1L are lost 400 
from SS18-SSX containing complexes following BRD9 degradation already suggests 401 
that BRD9 is essential for assembly of GBAF complexes. The specificity of the 402 
observed dependency on BRD9 containing complexes in synovial sarcoma cells is 403 
quite remarkable and bodes well for potential clinical applications in patients. 404 
Interestingly, a recent report indicated that malignant rhabdoid tumour (MRT) cells 405 
are also dependent on BRD9 function (44). Interestingly, MRTs and synovial 406 
sarcoma share a common feature, that being loss of SNF5. In essentially 100% of 407 
MRTs SNF5 is subject to biallelic inactivation; while in synovial sarcoma assembly of 408 
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SS18-SSX into BAF complexes leads to eviction and proteasomal degradation of 409 
SNF5. Since SNF5 is absent in BRD9 containing complexes it is tempting to 410 
speculate that loss of SNF5 (by genetic or biochemical means) shifts the balance of 411 
BAF complex assembly to a more GBAF-like state. This could explain the shared 412 
dependency on BRD9 function in these malignancies. Several additional cancers, 413 
including bladder cancer and uterine corpus endometrial carcinoma, have a high 414 
frequency of mutations effecting the genes encoding ARID1A/B (45). Loss of 415 
function mutations in these components could potentially shift the dynamics of BAF 416 
complex assembly toward a GBAF-like state. Therefore, it will be important to test 417 
the efficacy of BRD9 targeting in other cancers with BAF complex mutations. 418 
 419 
Most cancer treatments target processes important in normal and cancer cells, 420 
therefore toxicities resulting in debilitating side-effects remains problematic. Fusion 421 
gene driven cancers present a relatively unique opportunity to target cancer cell 422 
specific processes since oncogenic fusion proteins are present only in malignant 423 
cells. Understanding mechanisms related to fusion protein function may provide 424 
opportunities to develop therapies targeting underlying pathologies with limited 425 
effects on normal tissues. Our work demonstrates the importance of BRD9 in 426 
supporting SS18-SSX function and oncogenic gene expression in synovial sarcoma 427 
cells. Currently synovial sarcoma has few effective treatment options, and advanced 428 
forms of the disease have very poor overall survival. This study provides a rationale 429 
for development of BRD9 degradation as a novel therapeutic approach and 430 
potentially assessment in patients suffering with this disease. We demonstrate that 431 
degradation of BRD9, a member of an oncogenic multi-protein complex in synovial 432 
sarcoma, has a more profound effect on cancer cell survival than small-molecule 433 
mediated inhibition. This is an important point since inhibition of chromatin regulators 434 
such as EZH2, DOT1L and LSD1, which also exist in stable multi-protein complexes 435 
is currently under clinical investigation in several cancers (9, 46). Our findings 436 
suggest that inhibition, while effectively blocking a single functionality within a target 437 
protein, may provide a relatively ineffective means to block protein complex function 438 
as a whole. Scaffolding/other non-inhibited functions of a target protein may remain 439 
unaffected, allowing the target to continue supporting complex function. Therefore, 440 
degradation of proteins within multi-protein complexes may be a more efficacious 441 
approach in many cases. Importantly, the potent and selective small-molecule 442 
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inhibitors that already exist for proteins such as EZH2 and DOT1L will provide a 443 
basis for the development of novel protein degraders targeting these proteins. 444 
 445 
 446 
 447 
 448 
 449 
Materials and Methods 450 
 451 
Key Resources table: 452 
Reagent type 
(species) or 
resource 
Designation 
Source or 
reference 
Identifiers 
Additional 
information 
cell line (Homo 
sapiens) 
HEK293T ATCC 
RRID:CVCL_0063  
cell line (Homo 
sapiens) 
HSSYII 
  
Provided from the 
laboratory of Stefan 
Frohling 
cell line (Homo 
sapiens) 
SYO1 
  
Provided from the 
laboratory of Stefan 
Frohling 
cell line (Homo 
sapiens) 
1273/99 
  
Provided from the 
laboratory of Stefan 
Frohling 
cell line (Homo 
sapiens) 
A673 ATCC 
RRID:CVCL_0080  
cell line (Homo 
sapiens) 
CME1 
  
Provided from the 
laboratory of Stefan 
Frohling 
cell line (Homo 
sapiens) 
SKNMC ATCC 
RRID:CVCL_0530  
cell line (Homo 
sapiens) 
RH30 ATCC 
RRID:CVCL_0041  
cell line (Homo 
sapiens) 
RH41 DSMZ 
RRID:CVCL_2176  
antibody 
BRD9, rabbit 
polyclonal 
Bethyl Laboratories 
RRID:AB_11218396 
Western blotting 
(1:2500) and IP (5gs) 
antibody 
HA, rabbit 
monoclonal 
Cell Signalling 
Technologies 
RRIDA:AB_1549585 
Western blotting 
(1:1000) and ChIP (5-
10gs) 
antibody 
ACTIN, mouse 
monoclonal 
Cell Signalling 
Technologies 
RRID:AB_2750839 
Western blotting 
(1:5000) 
antibody 
CRBN, rabbit 
polyclonal 
Proteintech RRID:AB_2085739 
Western blotting 
(1:1000) 
antibody V5, rabbit polyclonal Bethyl Laboratories RRID:AB_67586 
Western blotting 
(1:1000) 
antibody 
SSX1, rabbit 
polyclonal 
MyBioscience RRID:AB_2750841 IP (10gs) 
antibody 
SSX2, rabbit 
polyclonla 
MyBioscience RRID:AB_2750840 IP (10gs) 
antibody 
SS18, rabbit 
polyclonal 
Santa Cruz 
Biotechnology 
RRID:AB_2195154 Western blotting (1:500) 
antibody 
H3K27Ac, rabbit 
polyclonal 
Abcam 
RRID:AB_2118291 
ChIP (5gs) 
antibody RNAPII, mouse Diagenode RRID:AB_2750842 ChIP (10s) 
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monoclonal 
other HA Pierce RRID:AB_2749815 IP affinity resin 
other V5 Sigma Aldrich RRID:AB_10062721 IP affinity resin 
chemical compound, 
drug 
dBRD9-A This study 
  
chemical compound, 
drug 
BI7273 Cayman Chemical 20311 
 
chemical compound, 
drug 
I-BRD9 Cayman Chemical 
17749  
chemical compound, 
drug 
X-termeGENE 9 Sigma Aldrich 
6365809001  
chemical compound, 
drug 
Formaldehyde Fisher Scientific 
BP531-500  
chemical compound, 
drug 
DSG Pierce 
20593  
chemical compound, 
drug 
ATPLite 1-Step Perkin Elmer 
6016731  
recombinant DNA 
reagent 
pPAX2 Addgene 
12260  
recombinant DNA 
reagent 
pCMV-VSV-G Addgene 
8454  
recombinant DNA 
reagent 
pLEX305 Addgene 
41390  
recombinant DNA 
reagent 
pLEX305-3xHA This study 
  
recombinant DNA 
reagent 
LRG2.0T This study 
 
Provided form the 
laboratory of Chris 
Vakoc 
recombinant DNA 
reagent 
SGEN 
MSKCC RNAi core 
facility   
recombinant DNA 
reagent 
pCR8 Invitrogen 
K250020  
recombinant DNA 
reagent 
pCR8-BRD9 (and 
derivatives) 
This study 
  
commercial assay or 
kit 
4-12% Bis-Tris gels Invitrogen 
NW04127BOX  
commercial assay or 
kit 
Q5 Site-Directed 
mutagenesis kit 
NEB E0554S 
 
commercial assay or 
kit 
ThruPlex DNA-seq kit Rubicon Genomics 
R400427  
commercial assay or 
kit 
Tapestation D1000 
screentape 
Agilent 
5067- 5584  
commercial assay or 
kit 
NextSeq 500 High 
Output v2 
Illumina FC-404-2005 
 
commercial assay or 
kit 
RNeasy mini-kit Qiagen 74106 
 
commercial assay or 
kit 
ERCC spike-in 
controls 
Ambion 
4456740  
commercial assay or 
kit 
NEBNext Ultra RNA 
library prep kit 
NEB E7530L 
 
commercial assay or 
kit 
BD Pharmingen BrdU 
Flow kit 
BD 
559619  
commercial assay or 
kit 
BD Annexin V 
Apoptosis detection 
kit 
BD 
556547 
 
software, algorithm 
ChIP and RNA-seq 
analysis 
Basepair 
 
www.basepair.io  
software, algorithm 
ChIP-seq data 
visualisation 
EaSeq 
 
https://easeq.net  
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strain, strain 
background (Mus 
musculus) 
BALB/c (Foxn1nu) 
Charles River 
Laboratory 
CAnN.Cg-
Foxn1nu/Crl  
 453 
 454 
 455 
 456 
 457 
 458 
Cell culture and lentiviral production: All cell lines were maintained at 37ºC in a 459 
humidified incubator. Lentiviral packaging HEK293T, synovial sarcoma (HSSYII, 460 
SYO1 and 1273/99) and Ewing’s sarcoma (A673) cell lines were cultured in DMEM 461 
(Gibco) media supplemented with 10% heat-inactivated fetal bovine serum (FBS), 462 
1% Penicillin-Streptomycin and 12.5ug/ml Plasmocin. Synovial sarcoma (CME1), 463 
Ewing’s sarcoma (SKNMC) and rhabdomyosarcoma (RH30 and RH41) cells were 464 
cultured in RPMI (Gibco) media supplemented with 10% heat-inactivated fetal bovine 465 
serum (FBS), 1% Penicillin-Streptomycin and 12.5ug/ml Plasmocin. Cell lines were 466 
tested regularly for mycoplasma contamination and tested negative in all cases. 467 
Lentiviral supernatants were generated by co-transfection of HEK293T cells with a 468 
lentiviral expression vector (cDNA, sgRNA or shRNA) with viral packaging (PAX2) 469 
and envelope (VSV-G) vectors using the X-tremegene transfection reagent (Roche) 470 
in accordance with the manufacturer’s instructions. Viral supernatants were collected 471 
between 24-48hrs post-transfection and used directly for infection of target cells after 472 
filtering through a 0.45µm syringe filter and addition of 8.5µg/ml Polybrene. 473 
 474 
Pooled CRISPR screening and data analysis: The human epigenetic domain U6-475 
sgRNA-EFS-GFP targeting library was pooled at equimolar ratio and used to 476 
generate lentiviral supernatant as described above. A dilution series of this virus 477 
correlated with GFP positivity in infected cells, and was used to derive an accurate 478 
viral multiplicity of infection (MOI). The total number of synovial and Ewing’s sarcoma 479 
target cells for infection was chosen to achieve at least 500-fold representation of 480 
each sgRNA in the initially infected cell population. To ensure that a single sgRNA 481 
was transduced per cell, the viral volume for infection was chosen to achieve an MOI 482 
of 0.3–0.4. Genomic DNA was extracted at the indicated time points using QiAamp 483 
DNA mini kit (Qiagen #51304), following the manufacturer’s instructions. To maintain 484 
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>500× sgRNA library representation, 16–20 independent PCR reactions were used 485 
to amplify the sgRNA cassette, which were amplified for 20 cycles with 100-200ng of 486 
starting gDNA using the 2× Phusion Master Mix (Thermo Scientific #F-548). The 487 
PCR products were pooled and end repaired with T4 DNA polymerase (NEB), DNA 488 
polymerase I (NEB), and T4 polynucleotide kinase (NEB). An A overhang was added 489 
to the end-repaired DNA using Klenow DNA Pol Exo- (NEB). The DNA fragment was 490 
then ligated with diversity-increased barcoded Illumina adaptors followed by 5 pre-491 
capture PCR cycles. Barcoded libraries were pooled at equal molar ratio and 492 
subjected to massively parallel sequencing using a Mi-Seq instrument (Illumina) 493 
using paired-end 150bp reads (MiSeq Reagent Kit v2; Illumina MS-102-2002). The 494 
sequence data were trimmed to contain only the sgRNA sequence then mapped to 495 
the reference sgRNA library without allowing any mismatches. The read counts were 496 
then calculated for each individual sgRNA. To compare the differential 497 
representation of individual sgRNAs between day 3 and day 15 time points, the read 498 
counts for each sgRNA were normalized to the counts of the negative control 499 
ROSA26 sgRNA.  500 
 501 
Cloning and mutagenesis: The human full-length BRD9 cDNA was PCR amplified 502 
from MGC clone 5428011 and inserted in the Gateway cloning compatible entry 503 
vector pCR8/GW/TOPO (Invitrogen, K250020)  in accordance with the 504 
manufacturer’s instructions. Clone integrity was confirmed by sanger sequence. 505 
Mutagenesis of the wildtype BRD9 sequence was performed using pCR8-BRD9 as 506 
template and the Q5 Site-Directed Mutagenesis Kit (NEB, E0554S) in accordance 507 
with the manufacturer’s instructions. Sequence verified BRD9 ORF sequences were 508 
subsequently cloned into the Gateway expression vector pLEX305 (Addgene vector, 509 
41390) which had been engineered to contain an N-terminal 3xHA epitope tag using 510 
LR clonase (Invitrogen, 12538120). 511 
 512 
Immunoprecipitation: Immunoprecipitations were performed as previously 513 
described (47). Briefly, nuclear pellets were lysed in buffer C containing protease 514 
inhibitors (20 mM HEPES at pH 7.6, 20% [v/v] glycerol, 0.42 M NaCl, 1.5 mM MgCl2, 515 
0.2 mM EDTA, aprotinin 1 μg mL−1, leupeptin 10 μg mL−1, PMSF 1 mM) and 516 
subsequently dialyzed against buffer C-100 (20 mM HEPES at pH 7.6, 20% [v/v] 517 
glycerol, 0.2 mM EDTA, 100 mM KCl, 1.5 mM MgCl2, 0.2 mM EDTA). Antibody-518 
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coupled beads were incubated with dialyzed nuclear extracts containing 250 U of 519 
benzonase (Sigma) for 3h at 4°C. Beads were then washed, and elutions were 520 
performed with 1xLDS buffer, 1 mg/mL HA peptide or 1mg/mL V5 peptide (Sigma). 521 
 522 
Mass spectrometry: In-solution tryptic digestions were performed as described 523 
previously(48). Peptides were analysed with a Q-Exactive mass spectrometer 524 
coupled with an EASY-nLC HPLC system (Thermo Fisher) and an in-house packed 525 
C18 column (New Objective). Parent ion spectra (MS1) were measured at resolution 526 
70,000, AGC target 3e6. Tandem mass spectra (MS2, up to 10 scans per duty cycle) 527 
were obtained at resolution 17,500, AGC target 5e4, collision energy of 25. All mass 528 
spectrometry data were processed using the MaxQuant software, version 1.3.0.5 529 
(49). The following search parameters were used; Fixed Mod: carbamidomethylation, 530 
Variable Mods: methionine oxidation, Trypsin/P digest enzyme, Precursor mass 531 
tolerances 6 ppm, Fragment ion mass tolerances 20 ppm, Peptide FDR 1%, Protein 532 
FDR 1%. 533 
 534 
Quantitative interaction proteomics in dBRD9-A treated cells: 535 
On bead digestion and mass spectrometry 536 
After the pulldown, the beads were resuspended in elution buffer (2M Urea, 100 mM 537 
Tris pH 8, 10 mM DTT) and incubated 20 min on a shaker (1300 rpm) at RT. After 538 
incubation, iodoacetamide was added to a final concentration of 50 mM, followed by 539 
10 min shaking in the dark at RT. Partial digestion and elution from the beads was 540 
initiated by adding 0.25 µg Trypsin (Promega; V5113) for 2 hours. The supernatant 541 
containing the IP samples was collected and the beads were resuspended in 50 µl 542 
elution buffer followed by a 5 min incubation shaking at RT. Both supernatants were 543 
combined and 0.1 µg Trypsin was added followed by overnight incubation at RT. The 544 
digestion was stopped by adding TFA (final concentration 0.5%). The resulting 545 
digested samples were desalted and purified using StageTips  (50). The peptides 546 
were eluted from StageTips with buffer B (80% acetonitrile, 0.1% formic acid), 547 
concentrated to 5 μL by SpeedVac centrifugation at room temperature, and filled up 548 
to 12 μL using buffer A (0.1% formic acid). Pulldown samples were measured using 549 
a gradient from 9-32% Buffer B for 114 minutes followed by washes at 50% then 550 
95% Buffer B, resulting in total 140 minutes data collection time. Mass spectra were 551 
recorded on an LTQ-Orbitrap Fusion Tribrid mass spectrometer (Thermo Fisher 552 
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Scientific). Scans were collected in data-dependent top speed mode with dynamic 553 
exclusion set at 60 seconds.  554 
Mass spectrometry analysis 555 
Thermo RAW files were analyzed with MaxQuant version 1.5.1.0 using default 556 
parameters. Searches were performed against the Uniprot mouse proteome, 557 
downloaded at June 2017. Additional parameters that were enabled were match-558 
between-runs, label-free quantification (LFQ) and IBAQ. After filtering for proteins 559 
that were present at least in all replicates of one condition, LFQ values were log2 560 
transformed and missing values were imputed in Perseus using default parameters 561 
(width = 0.3, shift = 1.8). Statistical outliers for the pulldowns were determined using 562 
a two-tailed t-test. Multiple testing correction was performed using a permutation-563 
based false discovery rate (FDR) method in Perseus. Volcano plots and 564 
stoichiometry calculations were performed as described previously (51).  565 
 566 
Chromatin immunoprecipitation: Cells for H3K27Ac and RNAPII ChIPs were fixed 567 
using 1% formaldehyde at room temperature for 10 mins. Formaldehyde crosslinking 568 
was quenched by adding Glycine to a final concentration of 0.125M directly to the 569 
fixation solution, followed by an additional 5 min incubation at room temperature. 570 
Cells for anti-HA (BRD9/SS18-SSX1) ChIPs were subjected to a 2-stage fixation; 571 
cells were initially fixed for 30 mins at room temperature using 0.5mM DSG, followed 572 
by an additional 10 mins at room temperature using 1% formaldehyde. 573 
Formaldehyde crosslinking was quenched as outlined above. Fixed cells were 574 
washed 2X with ice-cold PBS and pelleted by centrifugation. Nuclei were extracted 575 
by resuspending fixed cell pellets in LB1 buffer (50mm HEPES,140mm NaCl, 1mm 576 
EDTA, 10% Glycerol, 0.5% NP40, 0.25% Triton X100) containing 1X protease 577 
inhibitor cocktail (Biotools, B14002), followed by 10 mins incubation. Cells were 578 
pelleted by centrifugation and resuspended in LB2 buffer (10mM Tris ph8.0, 200mM 579 
NaCl, 1mM EDTA, 0.5mM EGTA) containing 1X protease inhibitor cocktail. Extracted 580 
nuclei were lysed using Covaris shearing buffer (0.1% SDS, 1mM EDTA and 10mM 581 
Tris pH 8.0) containing 1X protease inhibitor cocktail. Nuclei were lysed at a 582 
concentration of 10-30 million cells/ml in shearing buffer and sonicated in a Covaris 583 
E220, 1ml AFA milltubes (with fiber), Water level = 5, Duty Cycle = 5%, Peak 584 
Incidence Power = 140W, Cycle per burst = 200 for 16mins. Sonicated samples 585 
were pre-cleared by centrifugation at 14000rpm for 15mins at 4ºC. A 0.25X volume 586 
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of 5X ChIP buffer (250 mM HEPES, 1.5 M NaCl, 5 mM EDTA pH 8.0, 5% Triton X-587 
100, 0.5% DOC, and 0.5% SDS) was added to pre-cleared lysates, and these 588 
samples used directly for immunoprecipitations. For spike-in normalized ChIP 589 
experiments (ChIP-Rx) a 1:10 volume of fixed/sonicated chromatin derived for a 590 
mouse NIH3T3 cell line expressing a 3x HA epitope tagged BRD9 was added to 591 
each sample prior to the immunoprecipitation step. 592 
 593 
ChIP-seq library preparation and sequencing: ChIP purified DNA was quantified 594 
using a Qubit fluorimeter (Invitrogen), and 2-50ng of DNA/ChIP was used to 595 
generate ChIP-seq libraries with the ThruPLEX DNA-seq kit (Rubicon Genomics, 596 
R400427). Library DNA was quantified using the Qubit, and size distributions were 597 
ascertained on a Tapestation (Agilent) using the D1000 ScreenTape assay reagents 598 
(Agilent, 5067-5583). This information was used to calculate pooling ratios for 599 
multiplex library sequencing. Pooled libraries were diluted and processed for 75bp 600 
single-end sequencing on an Illumina NextSeq instrument using the NextSeq 500 601 
High Output v2 kit (75 cycle) (Illumina, FC-404-2005) in accordance with the 602 
manufacturer’s instructions. 603 
 604 
Cell count RNA-seq library prep and sequencing: Total RNA was isolated from 605 
cells using the RNeasy Mini Kit (Qiagen, 74106) in accordance with the 606 
manufacturer’s instructions. ERCC spike-in controls were added to isolated RNA to 607 
facilitate cell count normalization of RNA-sequencing data. The quality of extracted 608 
RNA was confirmed using a Bioanalyzer (Agilent) and 1g of total RNA was 609 
used/sample as library prep input. Libraries were generated using the NEBNext Ultra 610 
RNA Library Prep kit for Illumina (NEB, E7530L) in accordance with the 611 
manufacturer’s instructions. Library DNA was quantified using the Qubit, and size 612 
distributions were ascertained on a Tapestation (Agilent) using the D1000 613 
ScreenTape assay reagents (Agilent, 5067-5583). This information was used to 614 
calculate pooling ratios for multiplex library sequencing. Pooled libraries were diluted 615 
and processed for 75bp single-end sequencing on an Illumina NextSeq instrument 616 
using the NextSeq 500 High Output v2 kit (75 cycle) (Illumina, FC-404-2005) in 617 
accordance with the manufacturer’s instructions. 618 
 619 
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ChIP and RNA-seq data analysis: 620 
ChIP-seq analysis was performed using pipelines on the omics analysis platform 621 
Basepair (http://www.basepair.io). ChIP fastq files were trimmed to remove adapter 622 
and low quality sequences using trim_galore and aligned to the UCSC genome 623 
assembly hg19 using Bowtie (version 2.1.0). For spike-in normalized ChIP-seq 624 
experiments reads were separately aligned to hg19 and mm9 using Bowtie. 625 
Duplicate reads were removed using Picard Mark Duplicates. Peaks were detected 626 
using MACS (version 1.4) using a p value cutoff was set to 10-5. Peaks were 627 
annotated to genomic features (Promoter, Gene body, Intergenic) using custom 628 
scripts on the Basepair platform, based on the UCSC database for hg19. ChIP-seq 629 
data visualisations were generated using the EaSeq analysis software (52). 630 
 631 
RNA-seq fastq files were aligned to NCBI37/hg19 and normalized using STAR. 632 
Differential expression data were obtained using the DEseq algorithm. These 633 
analyses were all done through the Basepair analysis platform 634 
(http://www.basepair.io).  635 
 636 
Immunoblotting: Whole cell protein samples were prepared in RIPA buffer (25mM 637 
Tris-HCl. pH7.6, 150mM NaCl, 1% NP-40, 1% Sodium Deoxycholate, 0.1% SDS) 638 
containing 1X protease inhibitor cocktails. Protein lysates were separated on pre-639 
cast Bolt 4-12% Bis-Tris Plus Gels (Invitrogen, NW04127BOX) and transferred to 640 
nitrocellulose membranes. Membranes were subsequently probed using the relevant 641 
primary and secondary antibodies and relative protein levels were determined using 642 
the Odyssey CLx Imager (LI-COR). 643 
 644 
Cellular viability, cell cycle and apoptosis analysis: For dose response viability 645 
assays, cells were plated in 96-well tissue culture plates (1000 cells/well) in media 646 
containing DMSO or the desired concentration or each compound. Media was 647 
changed every 3-days up to a total of 9-days, at which point the ATPlite 1-Step 648 
luminescence assay system (PerkinElmer, 6016731) was used to determine ATP-649 
dependent luminescence as an approximation of cellular viability. For cell cycle and 650 
apoptosis analysis cells were initially seeded on 10cm dishes in media containing 651 
DMSO or 100nM dBRD9-A and cultured/passaged in this media for a total of 9 days. 652 
For cell cycle analysis control and treated cells were harvested at 3/6/9 days and 653 
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processed for FACs analysis using the BD Pharmingen BrdU Flow kit (BD, 559619) 654 
in accordance with the manufacturer’s instructions. For apoptosis analysis cells were 655 
harvested at 3/6/9 days (using Accutase to maintain cell membrane integrity) and 656 
processed for FACs analysis using the BD Annexin V Apoptosis Detection kit (BD, 657 
556547) in accordance with the manufacturer’s instructions. Stained cells were 658 
analysed on a BD LSRFortessa Cell Analyzer and data processed using FlowJo 659 
software. 660 
 661 
Mouse experiments: 4-6 week old female BALB/c (Foxn1nu) were purchased from 662 
Charles River Laboratories. For xenograft experiments mice were subcutaneously 663 
injected with 5 million synovial sarcoma cells in a 50/50 mix of culture 664 
media/matrigel. For treatment experiments dBRD9-A (50mg/kg) was administered 665 
once daily via intraperitoneal injection, over a total of 24 days. All experiments 666 
described were approved by and adhered to the guidelines of the Dana Farber 667 
Cancer Institute animal care and use committee.    668 
 669 
Antibodies: 670 
Antibodies used for Western blotting: rabbit anti-BRD9 polyclonal, Bethyl Labs 671 
(catalogue number: A303-781A), rabbit anti-HA monoclonal, Cell Signaling 672 
Technology (catalogue number: 3724S), mouse anti-ACTIN monoclonal, Cell 673 
Signaling Technology (catalogue number: 3700S), rabbit anti-CRBN polyclonal, 674 
Proteintech (catalogue number: 11435-1-AP), rabbit anti-V5 polyclonal, Bethyl Labs 675 
(catalogue number: A190-220A). Goat anti-Rabbit IgG polyclonal, LI-COR (catalogue 676 
number: 925-32211) and goat anti-Mouse IgG polyclonal, LI-COR (catalogue 677 
number: 926-68070). 678 
Antibodies used for IP: mouse anti-HA monoclonal magnetic beads, Pierce 679 
(catalogue number: 88837), mouse anti-V5 monoclonal agarose beads, Sigma 680 
(catalogue number: A7345-1ML), rabbit anti-BRD9 polyclonal, Bethyl Labs 681 
(catalogue number: A303-781A), rabbit anti-SSX1 polyclonal, MyBiosource 682 
(catalogue number: MBS9408371), rabbit anti-SSX2 polyclonal, MyBiosource 683 
(catalogue number: MBS9127222). 684 
 685 
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Antibodies used for ChIP: rabbit anti-HA monoclonal, Cell Signaling Technology 686 
(catalogue number: 3724S), rabbit anti-H3K27Ac polyclonal, Abcam (catalogue 687 
number: ab4729), mouse anti-RNAPII monoclonal, Diagenode (catalogue number: 688 
C15100055-100). 689 
 690 
Chemical synthesis of dBRD9-A 691 
 692 
4-bromo-2-methyl-2,7-naphthyridin-1(2H)-one 693 
To a fine suspension of 4-bromo-2-methyl-2,7-naphthyridin-1(2H)-one (996 mg, 4.43 694 
mmol, 1.0 eq) and Cesium Carbonate (4330 mg, 13.3 mmol, 3.0 eq) in THF (17.7 695 
mL) was added Iodomethane (551 L, 8.86 mmol, 2.0 eq) and stirred at RT. After 696 
22hrs, the mixture was concentrated in vacuo, and the resulting residue dissolved in 697 
DCM. Insoluble material was filtered and washed with both DCM and water before 698 
being discarded. Organic filtrate was collected (approx. 150mL), washed three times 699 
with deionized water (30 mL), and finally with saturated brine (30 millileters), before 700 
being dried over Na2SO4 and concentrated in vacuo to give the desired product as 701 
an off-white solid (1038 mg, 98%).  702 
1H NMR 1H NMR (500 MHz, DMSO-d6) δ = 9.36 (s, 1H), 8.88 (s, 1H), 8.25 (s, 1H), 703 
7.61 (s, 1H), 3.54 (s, 3H).  704 
LCMS: 239 (M). 705 
 706 
 707 
tert-butyl 2-((4-bromo-2,6-dimethoxybenzyl)(methyl)amino)acetate 708 
Sarcosyl tert-butyl ester hydrochloride (556 mg, 3.06 mmol, 1.5 eq) was dissolved in 709 
a solution of NaOAc (251 mg, 3.06 mmol, 1.5 eq), in DCM (8.2 mL), before 167 L 710 
AcOH  (2.04 mmol, 1.0 eq) was added, followed by 4-bromo-2,6-711 
dimethoxybenzaldehyde (500 mg, 2.04 mmol, 1.0 eq). The mixture was stirred for 10 712 
min before sodium triacetoxy borohydride was added in one portion (864.8 mg, 4.08 713 
mmol, 2.0 eq), and the mixture stirred for 18hr. The reaction was basified to 714 
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approximately pH 11 with 1M K2CO3 and extracted 4 times with DCM (10 mL). The 715 
combined organics were washed with deionized water (10 mL), and saturated brine 716 
(10 mL), before being dried over Na2SO4 and concentrated in vacuo to give the 717 
desired product as an off-white solid (725 mg, 95%).  718 
1H NMR (500 MHz, Chloroform-d) δ = 6.69 (s, 2H), 3.81 (s, 2H), 3.79 (s, 6H), 3.21 719 
(s, 2H), 2.41 (s, 3H), 1.48 (s, 9H).  720 
LCMS: 376 (M+H). 721 
 722 
 723 
tert-butyl 2-((2,6-dimethoxy-4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-724 
yl)benzyl)(methyl)amino)acetate 725 
tert-butyl 2-((4-bromo-2,6-dimethoxybenzyl)(methyl)amino)acetate (300 mg, 0.802 726 
mmol, 1.0 eq) and bis(pinacolato)diboron (305mg, 1.20 mmol, 1.5 eq), were 727 
dissolved in DMF, before KOAC (394 mg, 4.01 mmol, 5.0 eq), and PdCl2(dppf)  728 
CH2Cl2 (65.5 mg, 0.080 mmol, 0.1 eq) were added. The mixture was degassed, and 729 
headspace flushed with N2 before heating to 90°C for 16hr. The reaction was diluted 730 
to 80 mL with EtOAc, filtered through celite, and washed twice with a 1:1 solution of 731 
deionized water and saturated brine (20 mL), three times with deionized water (20 732 
mL), and once with saturated brine (20 mL), before being dried over Na2SO4 and 733 
concentrated in vacuo. The residue was dissolved in DCM and purified by silica 734 
chromatography (EtOAc/Hexanes 0 to 100% gradient) to give the desired product as 735 
a brown solid (158 mg, 47%).  736 
1H NMR: (500 MHz, Chloroform-d) δ = 6.98 (s, 2H), 3.90 (s, 2H), 3.85 (s, 6H), 3.20 737 
(s, 2H), 2.41 (s, 3H), 1.48 (s, 9H), 1.35 (s, 12H).  738 
LCMS: 423 (M+H).  739 
 740 
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 741 
tert-butyl 2-((2,6-dimethoxy-4-(2-methyl-1-oxo-1,2-dihydro-2,7-naphthyridin-4-742 
yl)benzyl)(methyl)amino)acetate 743 
4-bromo-2-methyl-2,7-naphthyridin-1(2H)-one (476 mg, 2.0 mmol, 1.0 eq) and tert-744 
butyl 2-((2,6-dimethoxy-4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-745 
yl)benzyl)(methyl)amino)acetate (1.01 g, 2.4 mmol, 1.2 eq) (prepared over multiple 746 
batches as above) were dissolved in DMF (10 mL) before a 2N solution of Na2CO3 747 
was added (2.5 mL, 5 mmol, 2.5 eq) followed by Pd(dppf)Cl2 • DCM (366 mg, 0.2 748 
mmol, 0.1 eq). The mixture was degassed and heated to 80°C overnight. Solvent 749 
was removed by lyophilization and the crude product was used directly. 750 
LCMS: 454 (M + H). 751 
 752 
 753 
2-((2,6-dimethoxy-4-(2-methyl-1-oxo-1,2-dihydro-2,7-naphthyridin-4-754 
yl)benzyl)(methyl)amino)acetic acid 755 
The above residue was dissolved in DCM (2 mL) before TFA (2 mL) was slowly 756 
added. After stirring at rt for 24 hours, the mixture was concentrated in vacuo. The 757 
residue was purified by prep-HPLC (0.05 % TFA) to give the desired product as an 758 
off-white solid (410 mg, 51 % over 2 steps)  759 
1H NMR (500 MHz, DMSO-d6) δ = 9.76 (s, 1H), 9.48 (s, 1H), 8.75 (d, 1H), 7.94 (s, 760 
1H), 7.64 (d, 1H), 6.87 (s, 2H), 4.42 (s, 2H), 4.02 (s, 2H), 3.87 (s, 6H), 3.63 (s, 3H), 761 
2.76 (s, 3H).  762 
LCMS: 398 (M+H). 763 
 764 
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 765 
4-((8-aminooctyl)amino)-2-(2,6-dioxopiperidin-3-yl)isoindoline-1,3-dione (4): 766 
To a solution of 2-(2,6-dioxopiperidin-3-yl)-4-fluoroisoindoline-1,3-dione (800 mg, 2.9 767 
mmol) and tert-butyl (8-aminooctyl)carbamate (710 mg, 2.9 mmol) in NMP (15 mL, 768 
0.2 M) was added DIPEA (451 mg, 3.5 mmol). The mixture was stirred at 90°C 769 
overnight, cooled to room temperature, diluted with EtOAc (100 mL), and washed 770 
with water (3 x 50 mL). The organic phase was washed with brine (50 mL), dried 771 
over anhydrous Na2SO4, and filtered. The filtrate was concentrated in vacuo, and 772 
the residue was stirred in TFA / CH2Cl2 (2 mL / 4 mL) for 2 hours at rt. The volatile 773 
was removed and the residue was purified by prep-HPLC (0.05 % TFA in CH3CN / 774 
H2O) to afford the desired product (687 mg, 46 %) as a yellow solid.  775 
1H NMR (500 MHz, Methanol-d4) δ 7.59 – 7.51 (m, 1H), 7.04 (dd, J = 7.9, 1.7 Hz, 776 
2H), 5.06 (dd, J = 12.4, 5.5 Hz, 1H), 3.34 (d, J = 7.0 Hz, 2H), 2.95 – 2.81 (m, 3H), 777 
2.79 – 2.66 (m, 2H), 2.15 – 2.08 (m, 1H), 1.67 (tt, J = 12.2, 7.2 Hz, 4H), 1.43 (d, J = 778 
22.2 Hz, 8H).  779 
LCMS 401.39 (M+H). 780 
 781 
 782 
dBRD9-A 783 
To a solution of 4-((8-aminooctyl)amino)-2-(2,6-dioxopiperidin-3-yl)isoindoline-1,3-784 
dione trifluoroacetate salt (669 mg, 1.3 mmol) and 2-((2,6-dimethoxy-4-(2-methyl-1-785 
oxo-1,2-dihydro-2,7-naphthyridin-4-yl)benzyl)(methyl)amino)acetic acid (520 mg, 1.3 786 
mmol) in DMF (5 mL) was added HATU (990 mg, 2.6 mmol) and DIPEA (516 mg, 4 787 
mmol). The mixture was stirred at rt. for 2 hours, diluted with ethyl acetate (50 mL), 788 
and washed with water (3 x 20 mL) and brine (20 mL), dried over anhydrous 789 
TFA-H2N
NH
N
NH
O
O
O
O
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Na2SO4, filtered and concentrated. The residue was purified by prep-HPLC (0.05 % 790 
TFA in CH3CN / H2O) to afford dBRD9-A (583 mg, 50 %) as a yellow solid.  791 
1H NMR (500 MHz, Methanol-d4) δ 9.54 (s, 1H), 8.67 (d, J = 6.1 Hz, 1H), 7.89 (s, 792 
1H), 7.77 (d, J = 6.0 Hz, 1H), 7.51 (dd, J = 8.5, 7.2 Hz, 1H), 6.99 (dd, J = 7.8, 2.2 Hz, 793 
2H), 6.84 (s, 2H), 5.48 (s, 2H), 5.03 (dd, J = 12.6, 5.5 Hz, 1H), 4.51 (d, J = 4.9 Hz, 794 
2H), 3.95 (s, 6H), 3.70 (s, 3H), 3.34 (s, 1H), 3.27 (t, J = 6.9 Hz, 2H), 2.92 (s, 3H), 795 
2.85 (ddd, J = 17.5, 13.9, 5.2 Hz, 1H), 2.76 – 2.65 (m, 2H), 2.13 – 2.06 (m, 1H), 1.61 796 
(p, J = 6.9 Hz, 2H), 1.52 – 1.46 (m, 2H), 1.43 – 1.25 (m, 11H).  797 
LCMS: 780.9 (M+H). 798 
 799 
Accession numbers 800 
All next-generation sequencing datasets generated in association with this work 801 
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Figure legends: 1008 
Figure 1: The BRD9 bromodomain is a functional dependency in synovial 1009 
sarcoma 1010 
A. Schematic representation of CRISPR/Cas9 based genomic screening approach.  1011 
B._Scatter plot representation of biological duplicate sgRNA screening data in 1012 
synovial and Ewing’s sarcoma cell lines. Each dot denotes and individual sgRNA 1013 
and axes represent log2 fold-change in sgRNA abundance between day-3 and day-1014 
15. BRD9 bromodomain and control sgRNAs are highlighted.  1015 
C._Schematic representation of the BRD9 protein structure with sgRNA target sites 1016 
indicated.  1017 
D. Negative selection based CRISPR-Cas9 mutagenesis assays. The relative GFP+ 1018 
(sgRNA+) subpopulation percentage is depicted at the indicated time-points after 1019 
lentiviral infection. Mean +/- s.d., n = 3.  1020 
E. Waterfall plot representing “BRD9 sensitivity” score in a panel of cancer cell lines 1021 
taken from the Project DRIVE database (ref. 18) 1022 
(https://oncologynibr.shinyapps.io/drive/).  1023 
F. Negative selection based CRISPR-Cas9 mutagenesis assays in bromodomain 1024 
functional rescue experiments. The relative GFP+ (sgRNA+) subpopulation 1025 
percentage is depicted at the indicated time-points after lentiviral infection. Mean +/- 1026 
s.d., n = 3. 1027 
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 1028 
Figure 2: BRD9 functions as part of SS18-SSX containing SWI/SNF complexes 1029 
A. Silver stains of endogenous SS18-SSX fusion protein immunoprecipitations 1030 
performed on nuclear protein lysates prepared 2 independent synovial sarcoma cell 1031 
lines. 1032 
B. Volcano plots representing fold enrichment (LFQ intensity) of proteins 1033 
identified by mass spec in SS18-SSX1 or SS18-SSX2 purifications relative to IgG 1034 
control purifications. Known BAF members are indicated in red. 1035 
C. Western blots analyses of the indicated proteins performed on endogenous 1036 
BRD9 or IgG purifications in HSSYII cells (Input = 10% total IP material). 1037 
D. Western blots analyses of the indicated proteins performed on endogenous 1038 
BRD9 or IgG purifications in SYO1 cells (Input = 10% total IP material). 1039 
E. Scatter plot representing the normalized protein abundance (IBAQ score) of 1040 
proteins identified in SS18-SSX1 and SS18-SSX2 purifications. Known BAF 1041 
members are indicated in red 1042 
F. High density sgRNA tiling of BRD9 in 2 independent SScell lines. Each bar 1043 
represents the fold-change of an individual sgRNA and its target site along the BRD9 1044 
protein. 1045 
G. Negative selection based CRISPR-Cas9 mutagenesis assays in amino acid 1046 
311-345 region functional rescue experiments. The relative GFP+ (sgRNA+) 1047 
subpopulation percentage is depicted at the indicated time-points after lentiviral 1048 
infection. Mean +/- s.d., n = 3. 1049 
H. Western blot analyses of the indicated proteins in anti-V5 purifications 1050 
performed in control HSSYII cells, or HSSYII cells expressing a full-length, 1051 
bromodomain deleted or amino acid 311-345 deleted BRD9. 1052 
 1053 
Figure 3: SS18-SSX1 and BRD9 co-bind the synovial sarcoma genome 1054 
A. Genomic tracks showing BRD9 and SS18-SSX1 ChIP-seq signal on the 98 1055 
Mb right arm of chromosome 8 in HSSYII cells. The chromosome 8 ideogram is 1056 
displayed above the gene tracks with the relevant region highlighted in red. 1057 
B. Pie charts representing the distribution of BRD9 and SS18-SSX1 binding sites 1058 
on the synovial sarcoma genome. 1059 
C. Venn diagram overlaps of all identified BRD9 and SS18-SSX1 ChIP-seq 1060 
peaks in HSSYII cells. 1061 
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D. Tornado plots showing BRD9, SS18-SSX1, RNAPII and H3K27Ac ChIP-1062 
signal +/- 10kb of all hg19 gene promoters in HSSYII cells. Promoters are ranked by 1063 
RNAPII ChIP signal. 1064 
E. Tornado plots showing BRD9, SS18-SSX1 and H3K27Ac ChIP-signal +/- 1065 
10kb of all active enhancers (defined by H327Ac) in HSSYII cells. 1066 
F. Tracks showing BRD9 and SS18-SSX1 ChIP-seq occupancy at the indicated 1067 
genomic loci in HSSYII cells.  1068 
 1069 
Figure 4: Complete ablation of BRD9 function by targeted protein degradation 1070 
A. Cellular viability dose-response data in the indicated panel of cell lines treated 1071 
with the BRD9 bromodomain inhibitors BI7273 (top) or I-BRD9 (bottom). Mean +/- 1072 
s.d., n = 3. 1073 
B. Tornado plots and meta-tracks representing BRD9 ChIP-Rx signal in control 1074 
(DMSO) and BI7273 treated (24hrs) HSSYII cells.  1075 
C. ChIP-qPCR analysis of 3xHA epitope tagged full-length BRD9, 311-345 1076 
BRD9 or  bromodomain BRD9 at the indicated gene promoters in HSSYII cells. 1077 
Mean +/- s.d., n = 3. 1078 
D. Chemical structure of our BRD9 degrader compound dBRD9-A. 1079 
E. Selectivity of phage-displayed bromodomain displacement by dBRD9-A 1080 
(Bromoscan). 1081 
F. Western blot analysis of the indicated proteins, in 2 independent synovial 1082 
sarcoma cell lines following treatment with dBRD9-A at 100nM for 6-72h. 1083 
G. Waterfall plot representing changes in BRD9 occupancy at BRD9 peak 1084 
regions in ChIP-Rx experiments of BI7273 (10M) (left panel) or dBRD9-A (100nM) 1085 
(right panel) treated HSSYII cells following 24hrs treatment. 1086 
H. Tracks showing BRD9 ChIP-seq occupancy on the 98 Mb right arm of 1087 
chromosome 8 after DMSO or 100nM dBRD9-A treatment. The chromosome 8 1088 
ideogram is displayed above the gene tracks with the relevant region highlighted in 1089 
red. 1090 
I. Cellular viability dose-response data in HSSYII and SYO1 cells treated with 1091 
dBRD9-A or the BRD9 bromodomain inhibitors BI7273 or I-BRD9. Mean +/- s.d., n = 1092 
3. 1093 
 1094 
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Figure 5: BRD9 degradation blocks synovial sarcoma tumour progression and 1095 
oncogenic transcription 1096 
A. Relative changes in cell cycle dynamics in 2 independent SS cell lines treated 1097 
with dBRD9-A for 3/6/9 days at 100nM. Mean +/- s.d., n = 3 1098 
B. Relative changes in Annexin-V positive cells in 2 independent SS cell lines 1099 
treated with dBRD9-A for 3/6/9 days at 100nM. Mean +/- s.d., n = 3 1100 
C. Tumour progression in a subcutaneous xenograft model of SS in control 1101 
vehicle treated mice, and mice treated at 50mg/kg dBRD9-A once daily for 24 days. 1102 
Mean +/- SEM, 5 mice per treatment group. P value is from 2way ANOVA 1103 
D. Western blot analysis of the indicated proteins in protein lysates derived from 1104 
tumour tissue from 2 independent mice per treatment group as in panel c. 1105 
E. Volcano plot representing gene expression changes in HSSYII cells treated 1106 
with dBRD9-A at 100nM for 6hrs. The number of genes, the expression of which 1107 
changes >1.5-fold up or down are indicated. 1108 
F. H3K27Ac ChIP-seq signal (rpm/bp) at all enhancer regions in HSSYII cell. 1109 
Enhancers are ranked by increasing H3K27Ac signal. 1110 
G. Box plot representations of changes in gene expression amongst genes 1111 
associated with typical enhancers and genes associated with super enhancers. P 1112 
values are from Welch’s two-tailed t-tests. ***P≤0.001. 1113 
H. Heat map representing changes in gene expression amongst all super 1114 
enhancer associated genes in HSSYII cells following 6hrs dBRD9-A treatment at 1115 
100nM, or HSSYII cells following infection with 2 independent SS18-SSX1 shRNAs 1116 
for 96hrs. 1117 
I. Tracks showing BRD9 and SS18-SSX1 ChIP-seq occupancy at the indicated 1118 
genomic loci in DMSO and dBRD9-A treated cells. Also shown is H3K27Ac ChIP-1119 
seq signal in untreated cells. 1120 
 1121 
Figure supplement legends: 1122 
Figure 1-figure supplement 1: BRD9 is a specific functional dependency in 1123 
synovial sarcoma 1124 
A. Scatter plot representation of sgRNA screening data in synovial and Ewing’s 1125 
sarcoma cell lines. Each dot denotes and individual bromodomain targeting sgRNA 1126 
and axes represent log2 fold-change in sgRNA abundance between day-3 and day-1127 
15. BRD4 and BRD9 bromodomain targeted sgRNAs are indicated. Highlighted 1128 
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region denotes sgRNAs depleted >2-fold in SS cells and unchanged in Ewing 1129 
sarcoma cells. 1130 
B. Indel quantification by TIDE (Tracking of Indels by sequence trace 1131 
Decomposition) analysis 4 days after transduction with the indicated sgRNA in the 1132 
indicated cell lines. Also presented are GFP FACs plots collected at time of 1133 
harvesting, demonstrating the proportion of GFP+ (sgRNA+) cells in each instance. 1134 
C. Western blot analysis of the indicated proteins in a cohort of synovial, and 1135 
non-synovial sarcoma cell lines. 1136 
D. Western blot analysis of the indicated proteins in 4 independent SS cell lines 1137 
expressing a control shRNA (Renilla) or one of two independent BRD9 targeting 1138 
shRNAs. 1139 
E. Negative selection-based shRNA functional assays in 4 independent SS cell 1140 
lines. The relative GFP+ (sgRNA+) subpopulation percentage is depicted at the 1141 
indicated time points after lentiviral infection. Mean +/- s.d., n = 3. 1142 
F. Western blots (as in Panel c) in Ewing sarcoma (A673) and 1143 
rhabdomyosarcoma (RH30) cells lines. 1144 
G. Negative selection-based shRNA assays (as in Panel e) in Ewing sarcoma 1145 
(A673) and rhabdomyosarcoma (RH30) cell lines. 1146 
H. Schematic representation of the BRD9 coding region targeted by sgRNA-15. 1147 
The sgRNA target sequence is highlighted in red and PAM sequence is indicated 1148 
(top). The silent mutations added to render the allele insensitive to CRISPR/Cas9 1149 
targeting are indicated, and sequence of the CRISPR-resistant allele shown 1150 
(bottom). 1151 
I. Western blot analysis of the indicated proteins in HSSYII cells used in function 1152 
rescue experiments. 1153 
 1154 
Figure 2-figure supplement 1: BRD9 is a component of SS18-SSX containing 1155 
BAF complexes. 1156 
A. Silver stains of anti-HA immunoprecipitations performed on nuclear protein 1157 
lysates prepared from HEK293T cell lines expression GFP (control) or an SS18-1158 
SSX1 or SS18-SSX2 fusion protein. 1159 
B. Volcano plots representing fold enrichment (LFQ intensity) of proteins 1160 
identified by mass spec in anti-HA-SS18-SSX1/2 purifications relative to GFP control 1161 
purifications. Known BAF members are indicated in red. 1162 
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C. Bar chart representing total peptide numbers identified for each of the 1163 
indicated BAF complex members in mass spec analysis of ant-HA-SS18-SSX1/2 1164 
purifications. 1165 
D. Bar chart representing total peptide numbers identified for each of the 1166 
indicated BAF complex members in mass spec analysis of endogenous SS18-1167 
SSX1/2 purifications. 1168 
E. Bar chart representing the fold-change in abundance of individual sgRNAs 1169 
targeting the bromodomains of the indicated BAF members between day-15 and 1170 
day-3 of our functional genomics screening experiments. 1171 
 1172 
Figure 3-figure supplement 1: BRD9 and SS18-SSX1 co-localise genome-wide 1173 
A. Schematic representation of the CRISPR/Cas9 mediated targeting of a 3xHA 1174 
epitope tag to the C-termini of the BRD9 and SS18-SSX1 loci. 1175 
B. Pie charts representing the proportion and total number of BRD9 and SS18-1176 
SSX1 ChIP-seq peaks occurring in each of the 3 indicated genomic regions. 1177 
C. Scatter plot representing the correlation of BRD9 and SS18-SSX1 ChIP-seq 1178 
signal within all identified BRD9 binding peaks. 1179 
D. Venn diagram overlap of all BRD9 and SS18-SSX1 target genes identified in 1180 
this study, with SS18-SSX1 targets identified in the work of Banito et al.,(21). 1181 
 1182 
Figure 4-figure supplement 1: Transcriptional regulation by BRD9 in SS cells 1183 
A. Tornado plots showing BRD9-WT and BRD9-N216A ChIP-signal signal within 1184 
all BRD9 peaks regions. Regions are ranked by change in ChIP-signal (BRD9-1185 
N216A/BRD9-WT). 1186 
B. Genomic tracks showing BRD9-WT and BRD9-N216A ChIP-seq signal at the 1187 
indicated locus in HSSYII cells. 1188 
C. Western blot analysis of the indicated proteins in wildtype or CRBN -/- 1189 
HEK293T cells treated with 100nM DBRD9-A for 0, 24 or 48hrs. 1190 
D. Western blot analysis of the indicated proteins in HSSYII cells treated with 1191 
increasing doses of dBRD9-A (100nM, 500nM) for 6h following pre-treatment of cells 1192 
for 12h with DMSO or BI7273 (5M). 1193 
E. Cellular viability dose-response data in SS (HSSYII and SYO1), Ewing 1194 
sarcoma (A673) and rhabdomyosarcoma (RH30) cell lines treated with dBRD9-A. 1195 
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Mean +/- s.d. n = 3. 1196 
F. Western blot analysis of the indicated proteins in Ewing (A673) and 1197 
rhabdomyosarcoma (RH30) cell lines treated with dBRD9-A at 100nM for 6 to 72h. 1198 
G. Western blot analyses of the indicated proteins in 2 independent synovial 1199 
sarcoma cell lines treated for the specified time course with BI7273 (left panels) at 1200 
5M or dBRD9-A (right panels) at 100nM.  1201 
H. Fold-change of all known BAF members identified by mass spectrometry in 1202 
SS18-SSX1 purifications performed in HSSYII cells treated with DMSO or dBRD9-A 1203 
for 24hrs.   1204 
 1205 
Figure 5-figure supplement 1: Targeted degradation of BRD9 1206 
A. Schematic representation of wildtype BRD9 and BRD7, and the chimeric 1207 
BRD9 bromodomain swap containing the BRD7 bromodomain (top panel). Western 1208 
blot analysis of the indicated proteins in HSSYII cells expressing vector (control), 1209 
BRD9-WT or BRD9 containing the bromodomain of BRD7 (BRD9-BD7) treated with 1210 
dBRD9-A at 100nM for 6h (bottom panel). 1211 
B. Growth assays of HSSYII cells (as in panel a) cultured in the presence of 1212 
dBRD9-A at 100nM for a total of 9-days. 1213 
C. Mouse weight measurements in vehicle control and dBRD9-A treated mice. 1214 
Mean +/- s.d., n = 5. 1215 
D. Complete blood counts (CBCs) performed on vehicle control and dBRD9-A 1216 
treated mice. Measurements were taken on day-23 of the 24-day treatment 1217 
experiment. Mean +/- s.d., n = 5. 1218 
E. Box plot representation of the relative abundance of BRD9 and SS18-SSX1 1219 
ChIP-seq signal at promoter, typical enhancer and super enhancer elements. P 1220 
values are from Welch’s two-tailed t-tests. *** P ≤0.001. 1221 
F. Box plot representations of changes in SS18-SSX1 occupancy at active 1222 
promoters, typical enhancers and super enhancers comparing DMSO and dBRD9-A 1223 
treated HSSYII cells. P values are from Welch’s two-tailed t-tests. *P ≤0.05, 1224 
***P≤0.001. 1225 
G. Venn diagram representing the proportion of overlap between all up/down-1226 
regulated genes (+/- 1.5-fold) in dBRD9-A treated cells at 6hrs post-treatment with all 1227 
direct SS18-SSX target genes. 1228 
 40 
 1229 
 1230 
 1231 
 1232 
 1233 
 1234 
 1235 
 1236 
 1237 
 1238 
 1239 
 1240 
 1241 
 1242 
 1243 
 1244 
 1245 
 1246 
 1247 
Source data: 1248 
Figure 1: 1249 
Figure 1-source data 1: Sequencing read counts and fold-change values for 1250 
individual sgRNAs in library experiments in HSSYII synovial sarcoma cells 1251 
 1252 
Figure 1-source data 2: Sequencing read counts and fold-change values for 1253 
individual sgRNAs in library experiments in A673 Ewing sarcoma cells 1254 
 1255 
Figure 1-source data 3: Relative GFP positive percentages in negative selection 1256 
sgRNA assays in 6 independent pediatric sarcoma cell lines 1257 
 1258 
Figure 1-source data 4: Relative GFP positive percentages in negative selection 1259 
sgRNA assays in BRD9-FL, BRD9-Dbromo or BRD9-N216A rescue experiments 1260 
performed in HSSYII cells 1261 
 1262 
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 1263 
Figure 2: 1264 
Figure 2-source data 1: Mass spectrometry data from endogenous SS18-SSX1 1265 
purifications in HSSYII cells 1266 
 1267 
Figure 2-source data 2: Mass spectrometry data from endogenous SS18-SSX2 1268 
purifications in SYO1 cells 1269 
 1270 
Figure 2-source data 3: Fold depletion of GFP positive cells in negative selections 1271 
sgRNA assays in HSSYII and SYO1 cells in BRD9 sgRNA tiling experiments 1272 
 1273 
Figure 2-source data 4: Relative GFP positive percentages in negative selection 1274 
sgRNA assays in BRD9-FL, BRD9-D311-345 rescue experiments performed in 1275 
HSSYII cells 1276 
 1277 
Figure 4: 1278 
Figure 4-source data 1: ChIP-qPCR data of HA-tagged BRD9 proteins - BRD9-FL, 1279 
BRD9 bromo and BRD9 311-345 - expressed in HSSYII cells.  1280 
Figure 5: 1281 
Figure 5-source data 1: Induction of apoptosis in HSSYII and SYO1 cells treated 1282 
with dBRD9-A at 100nM over 9-days.  1283 
 1284 
Figure 5-source data 2: Cell cycle dynamics of HSSYII and SYO1 cells treated with 1285 
dBRD9-A at 100nM over 9-days.  1286 
 1287 
Figure 5-source data 3: Gene expression changes in HSSYII cells treated with 1288 
dBRD9-A at 100nM for 6hrs 1289 
 1290 
Figure 2-figure supplement 1: 1291 
Figure 2-figure supplement 1-source data 1: Mass spectrometry data from SS18-1292 
SSX1 purifications in HEK293T cells 1293 
 1294 
Figure 2-figure supplement 1-source data 2: Mass spectrometry data from SS18-1295 
 42 
SSX2 purifications in HEK293T cells 1296 
 1297 
Figure 2-figure supplement 1-source data 3: Presented is the number of peptides 1298 
mapping to each of the indicated BAF complex members in purifications of HA-1299 
tagged SS18-SSX1 and SS18-SSX2 expressed in HEK293T cells 1300 
 1301 
Figure 2-figure supplement 1-source data 4: Presented is the number of peptides 1302 
mapping to each of the indicated BAF complex members in purifications of 1303 
endogenous SS18-SSX1 and SS18-SSX2 expressed in HSSYII and SYO1 cells 1304 
 1305 
Figure 4-figure supplement 1: 1306 
Figure 4-figure supplement 1-source data 1: Fold-change of individual BAF 1307 
complex members identified in SS18-SSX1 purifications from HSSYII cells treated 1308 
with DMSO or dBRD9-A at 100nM for 24hrs 1309 
 1310 
Figure 5-figure supplement 1: 1311 
Figure 5-figure supplement 1-source data 1: Cell counts in dBRD9-A treatment 1312 
experiments in HSSYII cells infected with an empty vector, a WT BRD9 expressing 1313 
vector or a BRD9 bromodomain swap (BRD7 bromodomain) vector 1314 
Figure 5-figure supplement 1-source data 2: Mouse weight measurement derived 1315 
from mice treated with control (vehicle) of dBRD9-A at 50mg/kg 1316 
 1317 
Figure 5-figure supplement 1-source data 3: Presented are blood counts derived 1318 
from DMSO and dBRD9-A treated mice 1 day prior to cessation of treatment 1319 
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